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Abstract: Mexiletine, a class 1b sodium channel blocker, has been used in cardiology since
the 1970’s, and is still in use for the prevention of (recurrent) ventricular tachycardia
(VT) and ventricular fibrillation (VF) in patients with cardiomyopathy and in patients
with Long QT syndrome. In addition, Mexiletine has been successfully used since
the 1980's in neurology, and specifically for non-dystrophic myotonia. The use
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of Mexiletine in non-dystrophic myotonia has received renewed interest, also from
the pharmaceutical industry, since randomised, placebo-controlled studies published
in 2012 and 2018. This finally resulted in a marketing authorisation of Mexiletine as
an orphan drug for non-dystrophic myotonia in 2018 by the European Medicines
Agency, and consequently resulted both in withdrawal of generic Mexiletine, prohibiting
of import, and in an exorbitant price increase, for both neurology and cardiology
patients. Likewise, European healthcare systems are forced to either accept, negotiate
or deny this price rise, and risk (further) problems in Mexiletine availability for patients
who depend on this drug for VT/VF prevention and risk problems in the delivery of
other care. This is just another example of continued misuse of orphan drug legislation
and should be prevented.
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Recently, patient access to mexiletine for the prevention of ventricular tachycardia (VT) and 
ventricular fibrillation (VF) has become critically endangered. This follows from the 
marketing authorisation by the European Medicines Agency (EMA) in December 2018 of 
mexiletine hydrochloride, now sold as ‘Namuscla’ by Lupin Europe GmbH, as an orphan 
drug for non-dystrophic myotonias.1 As such, the price of mexiletine has skyrocketed to about 
€65,000 per patient per year in European countries (price varying with dose and geographic 
location from €17,000 to €85,000), not only for patients with non-dystrophic myotonia but 
also for cardiology patients who, since the 1970’s,2 use mexiletine to prevent VT/VF. As a 
consequence, our social healthcare systems are suddenly burdened with another tremendous 
increase in healthcare costs for a drug previously priced at about €450-4400 per patient per 
year (either import or production). Noteworthy, this case only adds to our continuing troubles 
with drugs to prevent VT/VF (e.g. quinidine3). 
 
Commercial interest and regulatory incapability 
Regretfully, the mexiletine case (figure 1) is just another example of our regulatory 
incapability to withstand misuse of orphan drug legislation and regulation by exorbitant 
commercial interests in the treatment of patients with rare or common disease.3–7 Such 
interference of commercial interest with society healthcare can be illustrated as follows:  
 A healthcare’s inability to pay for excessive commercial prices of patented/novel or 
out-of-patent/conventional drugs with (regulated or effective) market exclusivity 
 A healthcare’s need to cut on other care to pay for excessive commercial prices of 
patented/novel or out-of-patent/conventional drugs with (regulated or effective) 
market exclusivity 
 ‘Evergreening’ of drug patents (e.g. by changing administration route, obtaining 
additional patents for new use or combinations) to prolong patent exclusivity. 
 Repurposing of drugs to new (orphan) indications, providing new patents or market 
exclusivity 
 Price gouging of out-of-patent drugs for (orphan) indications 
 Production stops of commercially unfavourable (orphan) drugs 
These commercial interferences with healthcare jeopardise any type of healthcare system 
throughout the world, and now mexiletine is threatened by commercial misuse of orphan drug 
regulation by appropriation of medical knowledge in the public domain.  
 
Insert figure 1. 
 
The cardiology case of mexiletine 
Mexiletine is one of the Vaughan Williams class 1b anti-arrhythmic drugs (a sodium channel 
blocker) that is available for the prevention of (recurrent) VT/VF in both ischemic and non-
ischemic cardiomyopathies and, more mechanism-specific, in Long QT syndrome (LQTS). 
Mexiletine had been developed in the late 1960’s, early 1970’s, by Boehringer Ingelheim and 
was quickly and successfully tested for the prevention of ventricular arrhythmias.2 However, 
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received benefit from mexiletine, limiting its use at that time.8,9 In 1995, mexiletine’s late 
sodium current blocking properties were successfully explored to decrease the QT-interval in 
LQTS-patients (in particular LQTS-type 3 based on an increased late inward sodium current10 
and later also in LQTS-type 211), to decrease their risk of VT/VF.11,12  
 
Although other anti-arrhythmic drugs have now widely surpassed mexiletine, it is currently 
still successfully, but incidentally, used for VT/VF prevention in patients with a 
cardiomyopathy and recurrent VT/VF when other pharmacological and/or invasive 
interventions fail. This life-saving potential of mexiletine is also very clear in LQTS-patients 
with severely prolonged QTc-intervals despite beta-blocker therapy and is used to avoid 
cardioverter defibrillator implantations. Consequently, mexiletine is still acknowledged in 
both European and United States guidelines for VT/VF and sudden cardiac death prevention, 
either as monotherapy or escalation therapy in addition to other anti-arrhythmic drugs and/or 
interventions.13,14  
 
The neurology case of mexiletine  
Non-dystrophic myotonias (prevalence <2:100,000 with distinct geographic variation) form a 
heterogenous group of rare diseases caused by mutations in skeletal muscle ion channels. The 
most striking hallmark of non-dystrophic myotonias is delayed skeletal muscle relaxation 
after voluntary contraction (the symptom of myotonia), resulting in functional limiting muscle 
stiffness, pain, fatigue, weakness and social impairment.15 
 
Due to the clear overlap of the electrophysiology of cardiac and skeletal muscle, it is of no 
surprise that anti-arrhythmic drugs can be used to treat neurological disorders. Similarly, 
neurological (and also psychotropic) drugs may result in cardiac (side-)effects16,17 and vice 
versa, because of their organ-unspecific impact on ion channels. As such, since the 1980’s 
many anti-arrhythmic drugs have been studied in small case series for the treatment of 
different types of myotonic disorders, with mexiletine as the most successful anti-myotonic 
drug.18 Ever since, off-label mexiletine is considered the first drug of choice for patients with 
non-dystrophic myotonias. 
 
In two recent, randomised, placebo-controlled studies in patients with non-dystrophic 
myopathy, published in 2012 and 2018, mexiletine was indeed effective for decreasing 
symptoms, increasing functional abilities and increasing social participation with less 
discomfort.15,19 Since, many more patients (from children to adults) with non-dystrophic 
myopathy are treated with mexiletine.  
  
 
Mexiletine as a commercial interest 
The European orphan drug legislation was launched in 2000 to stimulate development of 
medicinal products for rare diseases.20 Apart from protocol assistance and other incentives, 
10-year market exclusivity has indeed resulted in a considerable number of new treatments 
for rare disease that have frequently been accompanied by very high to outrageous prices.6,7 
Although meant to stimulate development of new drugs, this legislation has also enabled 
authorisation of old drugs for new indications that are subsequently sold at monopoly prices. 
It appears that the randomised study with mexiletine, published in 2012,15 spurred commercial 
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This story supposedly starts in 2010 when the mexiletine marketing authorisation in France 
was transferred from Boehringer Ingelheim France to Etablissement Pharmaceutique de l’AP-
HP (Assistance Publique - Hôpitaux de Paris) and labelled for symptomatic treatment of 
myotonic syndromes instead of ventricular arrhythmias.21 The French example, labelling 
mexiletine for myotonic disorders, was utilised by Temmler Pharma GmbH & Co. KG , 
Germany (now known as Aenova Group), to acquire an European orphan drug designation in 
2014 for mexiletine for the treatment of myotonic disorders.1 In 2015, when Lupin announced 
the acquirement of the specialty product portfolio of Temmler, which apparently included 
mexiletine, the product designation was transferred from Temmler to Hormosan Pharma 
GmbH, Germany (already acquired in 2008 by Lupin Group).1 In 2016 the product 
designation was transferred from Hormosan to Lupin (Europe) Limited, United Kingdom, and 
in 2018 it was transferred to Lupin Europe GmbH, Germany.1 Then, in December 2018, EMA 
granted marketing of Namuscla for the treatment of adult patients with non-dystrophic 
myotonia. Subsequently, in January 2019, the Etablissement Pharmaceutique de l’AP-HP 
ceased mexiletine delivery and transferred to Namuscla.22 Strikingly, the price of mexiletine 
skyrocketed when being sold as Namuscla.  
 
Catch 22 
Regretfully, the European marketing authorisation of Namuscla for non-dystrophic myotonia, 
now jeopardises the >40-year-old cardiological indication of mexiletine. In several European 
countries, mexiletine to prevent VT/VF is now only available as Namuscla at this outrageous 
price. Ironically, the official contra-indications of Namuscla1 list ventricular 
tachyarrhythmias, previous myocardial infarction and heart failure – mirroring one of the 
cardiology indications for mexiletine.  
 
Importantly, there are no alternative (outpatient) class 1b anti-arrhythmic drugs for the same 
indication to prevent VT/VF. Lidocaine only has similar properties and effects when 
administered intravenously (which is also one of the ways to quickly test the potency of 
mexiletine to decrease risk for arrhythmias), and is therefore no outpatient alternative, and 
phenytoin is solely indicated for arrhythmias due to digitalis intoxication.  
 
Orphan drugs in Europe—leaving no patient behind? 
‘Leaving no patient behind’ is one of EMA’s mottos. In this case, however, there are 
important consequences that may not have been clear to the authorities – although previous 
warnings have been provided.4–6 The rationale of the orphan drug legislation has been to 
promote commercial interest for new products for rare diseases and conditions, because 
without commercial interest the assumption is that such solutions will not be developed. 
Allowing labelling of (long) known drugs for orphan indications is only one of the caveats 
that terrorises healthcare systems on a large scale due to the, often exorbitant, price increases 
that accompany the commercial benefits associated with 10-year (orphan) drug market 
exclusivity.6,7 In addition, when drugs are used for multiple indications (e.g. non-dystrophic 
myotonia versus myotonic disorders in general), let alone in multiple specialties (e.g. 
neurology versus cardiology), market exclusivity for one indication translates to the same 
exorbitant price rises for the other indications – which easily doubles or triples the impact of 
such decisions. Because a healthcare budget is restricted, money spent on excessively priced 
orphan drugs cannot be spent on, e.g., wages of nurses, elderly or primary care initiatives, etc.  
 
The EMA recommendation, and European Commission decision, made with Namuscla 
therefore very much leaves patients behind, not only patients with non-dystrophic myotonia 
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outrageous price increase, as well as patients with other neurological or cardiology indications 
for mexiletine, as well as patients without a mexiletine indication who receive less net 
healthcare funding due to the drain of a budget by such price increase. Compellingly, the 
party that receives the financial benefits of this market exclusivity was not involved in the 
development of the drug nor in the investigations that led to the indications thereof (although 
it will probably have paid a significant price for this future asset).  
   
Possible solutions 
There are several possible solutions to this problem of misusing orphan drug legislation to 
gain orphan drug status for old drugs and/or known indications and charge high prices as a 
consequence of an orphan market exclusivity;  
1) exclude known indications or known use of existing drugs from orphan designation 
eligibility,  
2) introduce a ‘sufficiency test’ to define the line between sufficient and excessive 
profitability (the latter leading to withdrawal of orphan exclusivity),  
3) introduce sanctions by competition authorities against companies that abuse their (orphan) 
market position and/or engage in excessive pricing practices, and  
4) warrant that import or production of an affordable generic product (including active 
pharmaceutical ingredient) remains possible.  
 
In 2016, the European Council announced a review of the pharmaceutical incentives in the 
European Union. Suggestions have been made to re-instate a ‘withdrawal clause' into orphan 
drug legislation to protect quite specifically against pharmaceutical firms charging 
excessively high prices or making excessive profits.7 One should note that a company that 
obtains an (orphan) market exclusivity is under no obligation to demand an exorbitant price 
for its product. Indeed, a company that takes its responsibility in healthcare serious, would 
not. 
 
As an example of a potential solution, in South Korea the delivery and pricing problems with 
orphan and essential drugs has resulted in the national Korea Orphan Drug Centre which 
delivers drugs at a fraction of international prices; mexiletine for example is priced at about 
US $0,17/100mg, circa 200 times cheaper than Namuscla. In the USA, advanced legislation 
on exorbitant drug pricing has recently been put forward.23 
 
Conclusions 
Mexiletine has been used since the 1970’s for the prevention of (recurrent) VT/VF. The 2018 
EMA marketing authorisation of mexiletine as an orphan drug for non-dystrophic myotonia 
resulted both in withdrawal of generic mexiletine, prohibiting of import and in an exorbitant 
price increase, for both neurology and cardiology patients. Likewise, European healthcare 
systems are forced to either accept, negotiate or deny this price rise, and risk (further) 
problems in mexiletine availability for patients who depend on this drug for VT/VF 
prevention and risk problems in the delivery of other care. This is just another example of 
continued misuse of orphan drug legislation and should be prevented.  
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Figure and Legend 
Figure 1. Illustration of the Mexiletine case. Mexiletine has been long known to have life-
saving properties in patients with cardiomyopathy and recurrent VT, and in patients with 
Long QT syndrome, to decrease their risk of recurrent malignant arrhythmia. In addition, it 
has also successfully been used in neurology for non-dystrophic myotonia since decades, 
which was confirmed in a detailed 2012 publication in JAMA. Since the European marketing 
authorisation for neurology by EMA, its price skyrocketed.  
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